Madrigal Pharmaceuticals (NASDAQ:MDGL) Director Purchases $29,262,124.80 in Stock

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Bros. Advisors Lp Baker purchased 76,140 shares of the business’s stock in a transaction dated Friday, November 6th. The stock was bought at an average price of $384.32 per share, for a total transaction of $29,262,124.80. Following the completion of the acquisition, the director owned 2,040,682 shares of the company’s stock, valued at approximately $784,274,906.24. The trade was a 3.88% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.

Bros. Advisors Lp Baker also recently made the following trade(s):

• On Wednesday, November 4th, Bros. Advisors Lp Baker purchased 15,666 shares of Madrigal Pharmaceuticals stock. The stock was bought at an average cost of $367.71 per share, for a total transaction of $5,760,544.86.

Madrigal Pharmaceuticals Stock Performance

Shares of MDGL opened at $399.63 on Monday. Madrigal Pharmaceuticals, Inc. has a 1-year low of $353.54 and a 1-year high of $615.00. The company has a 50-day moving average of $486.74 and a 200 day moving average of $497.41. The firm has a market capitalization of $9.28 billion, a price-to-earnings ratio of -66.83 and a beta of -0.98. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.05 and a quick ratio of 2.78.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.09) by $2.92. The company had revenue of $431.27 million during the quarter, compared to analysts’ expectations of $404.17 million. Madrigal Pharmaceuticals had a negative net margin of 10.89% and a negative return on equity of 27.08%. During the same period in the previous year, the company earned ($5.08) EPS. On average, research analysts expect that Madrigal Pharmaceuticals, Inc. will post -2.08 EPS for the current year.

Institutional Investors Weigh In On Madrigal Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of MDGL. Janus Henderson Group PLC boosted its position in shares of Madrigal Pharmaceuticals by 27.4% in the 1st quarter. Janus Henderson Group PLC now owns 2,018,647 shares of the biopharmaceutical company’s stock worth $1,051,727,000 after purchasing an additional 433,804 shares in the last quarter. Jupiter Topco LLC purchased a new position in Madrigal Pharmaceuticals during the 2nd quarter worth $1,039,650,000. Paulson & CO. Inc. acquired a new position in Madrigal Pharmaceuticals during the 2nd quarter valued at about $719,524,000. BlackRock Inc. acquired a new position in Madrigal Pharmaceuticals during the 2nd quarter valued at about $644,753,000. Finally, Wellington Management Group LLP increased its position in Madrigal Pharmaceuticals by 18.8% during the 2nd quarter. Wellington Management Group LLP now owns 825,714 shares of the biopharmaceutical company’s stock valued at $443,367,000 after buying an additional 130,756 shares in the last quarter. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on MDGL shares. The Goldman Sachs Group assumed coverage on Madrigal Pharmaceuticals in a research note on Thursday, September 24th. They set a “buy” rating and a $704.00 price target on the stock. UBS Group reaffirmed a “buy” rating and issued a $735.00 price objective on shares of Madrigal Pharmaceuticals in a research note on Wednesday, October 14th. Barclays dropped their target price on shares of Madrigal Pharmaceuticals from $964.00 to $962.00 and set an “overweight” rating on the stock in a report on Monday, August 3rd. Citigroup raised their target price on shares of Madrigal Pharmaceuticals from $725.00 to $760.00 and gave the company a “buy” rating in a research report on Tuesday, November 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a report on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $706.87.

More Madrigal Pharmaceuticals News

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Multiple real-world studies presented at AASLD reported improvements in liver stiffness and cardiometabolic health markers among patients treated with Rezdiffra, supporting the drug’s real-world potential. Rezdiffra real-world data
• Positive Sentiment: Madrigal’s latest quarterly results beat estimates: EPS was $1.83 versus consensus of a $1.09 loss, and revenue of $431.3 million exceeded the $404.2 million estimate. Madrigal stock jumps after earnings beat
• Positive Sentiment: HC Wainwright reiterated a Strong-Buy rating and projected rising EPS through 2030; Canaccord Genuity also raised its price target to $633 and maintained a Buy rating. These forecasts point to optimism about future growth, though they are analyst expectations, not guarantees.
• Neutral Sentiment: General Counsel Shannon Kelley sold 1,077 shares for about $430,800 under a pre-arranged Rule 10b5-1 plan. Kelley retained 10,397 shares, which may temper concern about the sale.
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations after Madrigal’s November 3 quarterly filing. These are investigations and investor solicitations—not findings of wrongdoing—but could create legal and reputational uncertainty. Securities investigation announcement

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. The company is headquartered in Conshohocken, Pennsylvania.

Its lead product, Rezdiffra (resmetirom), is a thyroid hormone receptor-beta agonist. The U.S. Food and Drug Administration approved Rezdiffra in 2024 for use with diet and exercise in adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis.

Madrigal’s work centers on advancing medicines for liver disease, with Rezdiffra serving as its first approved therapy.